Biogen Inc (BIIB)

BIIB (NASDAQ:Drugs) EQUITY
$273.68
neg -1.30
-0.48%
Today's Range: 268.88 - 274.99 | BIIB Avg Daily Volume: 1,803,300
Last Update: 05/02/16 - 3:59 PM EDT
Volume: 1,358,789
YTD Performance: 0.00%
Open: $274.61
Previous Close: $274.99
52 Week Range: $242.07 - $420.99
Oustanding Shares: 219,051,491
Market Cap: 61,570,993,090
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 10 10 11
Moderate Buy 2 2 2 2
Hold 6 8 8 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.75 1.88 1.88 1.77
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 0.00
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
0.00 17.30 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.00% 0.00% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 10.80 0.90 0.25
Net Income 22.20 1.60 0.37
EPS 24.00 1.60 0.38
Earnings for BIIB:
EBITDA 4.28B
Revenue 9.42B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $4.67 $4.74 $18.96 $20.28
Number of Analysts 22 22 22 22
High Estimate $5.29 $5.33 $20.80 $22.70
Low Estimate $4.41 $4.49 $18.40 $19.13
Prior Year $4.22 $4.48 $17.01 $18.96
Growth Rate (Year over Year) 10.70% 5.92% 11.49% 6.91%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
BIIB could be headed above $300 over the intermediate term.

Some Stocks Are Really Cheap Real Money Pro($)

There are lots of winners in the first quarter.
Bearish
Apr 22, 2016 | 7:25 AM EDT
Shares of BIIB now seen reaching $319, according to Leerink Partners. Estimates also reduced, as the MS franchise is facing pressure. M...
Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.
With Pfizer deal dead, Allergan is ready to go shopping.
The lack of fear, by way of the VIX, speaks volumes about where the market is headed.
Let's also take a look at Biogen, a biotech I like.
The biotech company's shares remain range-bound, but a fresh rally appears to be brewing.

Markers Spotted Point to a Top Real Money Pro($)

At the very least, move those stop loss levels in very close on long positions.
The group rallied yesterday, but it's still not out of the woods.

Columnist Conversations

That could put an axe into the stock here near 30x forward earnings.  Comps were OK though, at over 5% in...
CIRCOR International (CIR) ripping into the close on a basic upgrade.  The stock has basically doubled in...
As we have previously said, Apple (AAPL) is inside our long-term bounce zone of $94.74-$85.36. I know the zone...
Average Cost= $20.22 Bidding on a scale lower.

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.